Babesia DNA was detected in 24% of a 50‑patient cohort with at least six months of fatigue and concurrent neurologic symptoms in an IRB‑approved study from North Carolina State University. Participants submitted three blood samples over a week that were cultured and PCR‑tested. The study population was selected from a larger group that self‑reported chronic disease and arthropod exposure, indicating an enriched cohort rather than a general chronic fatigue population. No treatment outcomes were reported.
On the back of this prevalence signal, 60 Degrees Pharmaceuticals is advancing the B‑Free Chronic Babesiosis Study (NCT06656351), a prospective trial evaluating a 90‑day regimen of tafenoquine (marketed as ARAKODA for malaria prophylaxis) for resolution of severe fatigue in patients characterized as having chronic babesiosis. The study is now enrolling at the Icahn School of Medicine at Mount Sinai. Tafenoquine is not approved for babesiosis, and the company partially funded the North Carolina study.
The strategic bet is clear: leverage rising babesiosis incidence and a growing focus on persistent post‑infection syndromes to position tafenoquine—an 8‑aminoquinoline with a long half‑life and tissue activity—as a potential option in a space with no FDA‑approved therapies. The company is using a small, enriched diagnostic study to support continued investment in a label‑expansion path where conventional short‑course regimens can struggle and where fatigue‑forward endpoints could differentiate. The risk is equally obvious: causality between Babesia positivity and chronic fatigue is unproven, diagnostic sensitivity and specificity vary across assays, and fatigue as a primary outcome in an infectious disease trial will face heightened scrutiny unless paired with robust microbiologic clearance and functional measures.
For sites, this program carries practical implications. Tafenoquine requires G6PD testing to mitigate hemolysis risk, adding screening complexity and turnaround time. The 90‑day duration and a likely PRO‑driven primary endpoint will demand adherence support, frequent patient‑reported data capture, and consistent use of validated instruments. Sites will also need access to reliable, centralized PCR testing capable of serial quantitation, since regulators will expect alignment between symptom change and parasite dynamics. Chronic fatigue clinics could become recruitment hubs, but eligibility hinges on a defensible case definition of chronic babesiosis, which remains a moving target.
Sponsors and CROs will need to solve for diagnostics as much as drug: standardized PCR methodology, blinding procedures for lab personnel, and pre‑specified thresholds for positivity that avoid conflating transient low‑level parasitemia with clinically meaningful infection. Comparator strategy will matter. Without a randomized arm against current off‑label standards such as atovaquone plus azithromycin, read‑through to regulatory acceptability will be limited. If the study proceeds single‑arm, the bar for objective endpoints—parasitemia clearance, relapse rates, hospitalization avoidance—will rise. Safety monitoring must account for tafenoquine’s long half‑life, particularly in the context of neuropsychiatric and hematologic adverse events, and will shape consent and follow‑up windows.
The near‑term watchlist is straightforward. Final protocol disclosures should clarify the primary endpoint hierarchy, the fatigue instrument, and whether microbiologic clearance is co‑primary or key secondary. Details on assay validation and central lab oversight will signal regulatory readiness. Early recruitment velocity at Mount Sinai will indicate whether the field can operationalize a chronic babesiosis definition at scale. Any interim analysis pairing symptom change with sustained PCR negativity would materially de‑risk the program; absent that linkage, expectations should remain guarded. If the company can align on endpoints with FDA and demonstrate durable clearance alongside functional improvement, it could open a path in an orphan, fast‑growing indication. If not, the field risks another loop of small signals without regulatory traction, prolonging off‑label reliance and diagnostic ambiguity.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
